Thrombotische Mikroangiopathie

• Literatur

• 1 Bendapudi PK, Hurwitz S, Fry A. et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017; 4: e157-164
• 2 Wendt R, Kalbitz S, Otto F. et al. Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker. Frontiers Medicine 2021; 8: 639441
• 3 Noris M, Galbusera M, Gastoldi S. et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-1726
• 4 Coppo P, Schwarzinger M, Buffet M. et al. Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience. Plos One 2010; 5: e10208
• 5 Riedl M, Fakhouri F, Quintrec ML. et al. Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. Semin Thromb Hemost 2014; 40: 444-464
• 6 Legendre CM, Licht C, Muus P. et al. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome. New Engl J Medicine 2013; 368: 2169-2181
• 7 Walle JV, Delmas Y, Ardissino G. et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017; 30: 127-134
• 8 Fakhouri F, Loirat C. Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Semin Hematol 2018; 55: 150-158
• 9 Fakhouri F, Hourmant M, Campistol JM. et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Am J Kidney Dis 2016; 68: 84-93
• 10 Menne J, Delmas Y, Fakhouri F. et al. Eculizumab prevents thrombotic microangiopathy in patients with typical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J 2018; 12: sfy035
• 11 McNamara LA, Topaz N, Wang X. et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. Am J Transplant 2017; 17: 2481-2484
• 12 Patriquin CJ, Kulasekararaj A, Latour RP. et al. Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry. Blood 2019; 134: 4802-4802
• 13 Matsumura Y. Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database. Drug Healthc Patient Saf 2020; 12: 207-215
• 14 Rondeau E, Scully M, Ariceta G. et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 2020; 97: 1287-1296
• 15 Völker LA, Kaufeld J, Balduin G. et al. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost 2022;
• 16 Kielstein JT, Beutel G, Fleig S. et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transpl 2012; 27: 3807-3815